1-2 of 2
Mark Erlander, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Tara L. Lin, MD, Pamela S. Becker, MD PhD, Prapti A. Patel, MD, Eunice S. Wang, MD, Alexander I. Spira, PhD MD FACP, Michaela L. Tsai, MD, Maya Ridinger, Peter J Croucher, PhD, Mark Erlander, PhD, Sandra L Silberman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 230.
https://doi.org/10.1182/blood-2019-126262
Published: 2019
Journal Articles

Preliminary Safety, Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of the Polo-like Kinase-1 (PLK1) Inhibitor PCM-075, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (D) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Alexander I Spira, MD, Prapti A. Patel, MD, Michaela L. Tsai, MD, Maya Ridinger, PhD, Sandra L Silberman, MD PhD, Mark Erlander, PhD, Jorge E. Cortes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4043.
https://doi.org/10.1182/blood-2018-99-112590
Published: 2018